Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Daniel William Cramer, Sc.D., M.D.

Co-Author

This page shows the publications co-authored by Daniel Cramer and Kathryn Terry.
Connection Strength

6.871
  1. Telomere length and genetic variation in telomere maintenance genes in relation to ovarian cancer risk. Cancer Epidemiol Biomarkers Prev. 2012 Mar; 21(3):504-12.
    View in: PubMed
    Score: 0.491
  2. Incessant ovulation, mucin 1 immunity, and risk for ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2007 Jan; 16(1):30-5.
    View in: PubMed
    Score: 0.346
  3. Common Analgesic Use for Menstrual Pain and Ovarian Cancer Risk. Cancer Prev Res (Phila). 2021 08; 14(8):795-802.
    View in: PubMed
    Score: 0.237
  4. Intrauterine device use and risk of ovarian cancer: Results from the New England Case-Control study and Nurses' Health Studies. Int J Cancer. 2021 07 01; 149(1):75-83.
    View in: PubMed
    Score: 0.232
  5. Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA. Cancer Causes Control. 2021 Mar; 32(3):299-309.
    View in: PubMed
    Score: 0.229
  6. Peripheral Blood Leukocyte Telomere Length and Endometriosis. Reprod Sci. 2020 10; 27(10):1951-1959.
    View in: PubMed
    Score: 0.220
  7. Association Between Breastfeeding and Ovarian Cancer Risk. JAMA Oncol. 2020 06 01; 6(6):e200421.
    View in: PubMed
    Score: 0.219
  8. Development and validation of circulating CA125 prediction models in postmenopausal women. J Ovarian Res. 2019 Nov 26; 12(1):116.
    View in: PubMed
    Score: 0.212
  9. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2019 06 01; 48(3):822-830.
    View in: PubMed
    Score: 0.204
  10. Predicting Circulating CA125 Levels among Healthy Premenopausal Women. Cancer Epidemiol Biomarkers Prev. 2019 06; 28(6):1076-1085.
    View in: PubMed
    Score: 0.202
  11. Statin therapy and association with ovarian cancer risk in the New England Case Control (NEC) study. Int J Cancer. 2019 03 01; 144(5):991-1000.
    View in: PubMed
    Score: 0.196
  12. Chronic Medical Conditions and CA125 Levels among Women without Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2018 12; 27(12):1483-1490.
    View in: PubMed
    Score: 0.195
  13. Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort. Cancer Epidemiol Biomarkers Prev. 2018 07; 27(7):790-804.
    View in: PubMed
    Score: 0.189
  14. Menstrual pain and risk of epithelial ovarian cancer: Results from the Ovarian Cancer Association Consortium. Int J Cancer. 2018 02 01; 142(3):460-469.
    View in: PubMed
    Score: 0.182
  15. Correlates of circulating ovarian cancer early detection markers and their contribution to discrimination of early detection models: results from the EPIC cohort. J Ovarian Res. 2017 Mar 20; 10(1):20.
    View in: PubMed
    Score: 0.176
  16. Predictors of pretreatment CA125 at ovarian cancer diagnosis: a pooled analysis in the Ovarian Cancer Association Consortium. Cancer Causes Control. 2017 May; 28(5):459-468.
    View in: PubMed
    Score: 0.173
  17. Long and irregular menstrual cycles, polycystic ovary syndrome, and ovarian cancer risk in a population-based case-control study. Int J Cancer. 2017 Jan 15; 140(2):285-291.
    View in: PubMed
    Score: 0.170
  18. The Association Between Talc Use and Ovarian Cancer: A Retrospective Case-Control Study in Two US States. Epidemiology. 2016 May; 27(3):334-46.
    View in: PubMed
    Score: 0.165
  19. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clin Cancer Res. 2016 Sep 15; 22(18):4664-75.
    View in: PubMed
    Score: 0.164
  20. Polymorphisms of MUC16 (CA125) and MUC1 (CA15.3) in relation to ovarian cancer risk and survival. PLoS One. 2014; 9(2):e88334.
    View in: PubMed
    Score: 0.142
  21. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer. Gynecol Oncol. 2014 Mar; 132(3):542-50.
    View in: PubMed
    Score: 0.141
  22. Correlates of the preoperative level of CA125 at presentation of ovarian cancer. Gynecol Oncol. 2010 Dec; 119(3):462-8.
    View in: PubMed
    Score: 0.112
  23. Breast cancer susceptibility alleles and ovarian cancer risk in 2 study populations. Int J Cancer. 2009 Feb 01; 124(3):729-33.
    View in: PubMed
    Score: 0.100
  24. High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2022 02; 31(2):443-452.
    View in: PubMed
    Score: 0.061
  25. Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2021 09; 30(9):1669-1680.
    View in: PubMed
    Score: 0.059
  26. Self-reported infertility diagnoses and treatment history approximately 20 years after fertility treatment initiation. Fertil Res Pract. 2021 Mar 12; 7(1):7.
    View in: PubMed
    Score: 0.058
  27. Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. J Natl Cancer Inst. 2021 03 01; 113(3):301-308.
    View in: PubMed
    Score: 0.058
  28. Co-occurrence of immune-mediated conditions and endometriosis among adolescents and adult women. Am J Reprod Immunol. 2021 07; 86(1):e13404.
    View in: PubMed
    Score: 0.058
  29. Depot-Medroxyprogesterone Acetate Use Is Associated with Decreased Risk of Ovarian Cancer: The Mounting Evidence of a Protective Role of Progestins. Cancer Epidemiol Biomarkers Prev. 2021 05; 30(5):927-935.
    View in: PubMed
    Score: 0.058
  30. Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecol Oncol. 2020 09; 158(3):702-709.
    View in: PubMed
    Score: 0.055
  31. Estrogen Plus Progestin Hormone Therapy and Ovarian Cancer: A Complicated Relationship Explored. Epidemiology. 2020 05; 31(3):402-408.
    View in: PubMed
    Score: 0.054
  32. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Med. 2019 05; 8(5):2503-2513.
    View in: PubMed
    Score: 0.051
  33. Joint exposure to smoking, excessive weight, and physical inactivity and survival of ovarian cancer patients, evidence from the Ovarian Cancer Association Consortium. Cancer Causes Control. 2019 May; 30(5):537-547.
    View in: PubMed
    Score: 0.050
  34. A comprehensive gene-environment interaction analysis in Ovarian Cancer using genome-wide significant common variants. Int J Cancer. 2019 05 01; 144(9):2192-2205.
    View in: PubMed
    Score: 0.050
  35. rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. Int J Mol Sci. 2018 Aug 21; 19(9).
    View in: PubMed
    Score: 0.048
  36. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS One. 2018; 13(7):e0197561.
    View in: PubMed
    Score: 0.048
  37. Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. Br J Cancer. 2018 04; 118(8):1123-1129.
    View in: PubMed
    Score: 0.047
  38. Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation. Int J Cancer. 2018 08 01; 143(3):515-526.
    View in: PubMed
    Score: 0.047
  39. Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol. 2018 02 01; 187(2):366-377.
    View in: PubMed
    Score: 0.047
  40. Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium. Cancer Sci. 2018 Feb; 109(2):435-445.
    View in: PubMed
    Score: 0.047
  41. Ovarian cancer early detection by circulating CA125 in the context of anti-CA125 autoantibody levels: Results from the EPIC cohort. Int J Cancer. 2018 04 01; 142(7):1355-1360.
    View in: PubMed
    Score: 0.046
  42. Polycystic Ovary Syndrome, Oligomenorrhea, and Risk of Ovarian Cancer Histotypes: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2018 02; 27(2):174-182.
    View in: PubMed
    Score: 0.046
  43. History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2017 09; 26(9):1470-1473.
    View in: PubMed
    Score: 0.045
  44. History of thyroid disease and survival of ovarian cancer patients: results from the Ovarian Cancer Association Consortium, a brief report. Br J Cancer. 2017 Sep 26; 117(7):1063-1069.
    View in: PubMed
    Score: 0.045
  45. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget. 2017 Jun 15.
    View in: PubMed
    Score: 0.045
  46. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. Oncotarget. 2017 Sep 12; 8(39):64670-64684.
    View in: PubMed
    Score: 0.045
  47. Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. Br J Cancer. 2017 Apr 25; 116(9):1223-1228.
    View in: PubMed
    Score: 0.044
  48. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nat Genet. 2017 May; 49(5):680-691.
    View in: PubMed
    Score: 0.044
  49. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes Control. 2017 May; 28(5):469-486.
    View in: PubMed
    Score: 0.044
  50. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int J Cancer. 2017 06 01; 140(11):2422-2435.
    View in: PubMed
    Score: 0.043
  51. Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. Br J Cancer. 2017 Feb 14; 116(4):524-535.
    View in: PubMed
    Score: 0.043
  52. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget. 2016 11 08; 7(45):72381-72394.
    View in: PubMed
    Score: 0.043
  53. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget. 2016 10 25; 7(43):69097-69110.
    View in: PubMed
    Score: 0.043
  54. Risk Prediction for Epithelial Ovarian Cancer in 11 United States-Based Case-Control Studies: Incorporation of Epidemiologic Risk Factors and 17 Confirmed Genetic Loci. Am J Epidemiol. 2016 Oct 15; 184(8):579-589.
    View in: PubMed
    Score: 0.043
  55. No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiol Biomarkers Prev. 2017 03; 26(3):420-424.
    View in: PubMed
    Score: 0.042
  56. A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. Int J Cancer. 2016 Dec 15; 139(12):2646-2654.
    View in: PubMed
    Score: 0.042
  57. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nat Commun. 2016 09 07; 7:12675.
    View in: PubMed
    Score: 0.042
  58. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS. J Med Genet. 2016 12; 53(12):800-811.
    View in: PubMed
    Score: 0.042
  59. Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016 10; 45(5):1619-1630.
    View in: PubMed
    Score: 0.042
  60. Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. Int J Epidemiol. 2016 06; 45(3):884-95.
    View in: PubMed
    Score: 0.042
  61. Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Hum Mol Genet. 2016 08 15; 25(16):3600-3612.
    View in: PubMed
    Score: 0.042
  62. Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. Br J Cancer. 2016 06 28; 115(1):95-101.
    View in: PubMed
    Score: 0.042
  63. Chronic Recreational Physical Inactivity and Epithelial Ovarian Cancer Risk: Evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiol Biomarkers Prev. 2016 07; 25(7):1114-24.
    View in: PubMed
    Score: 0.041
  64. Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstet Gynecol. 2016 05; 127(5):828-836.
    View in: PubMed
    Score: 0.041
  65. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet. 2016 07; 135(7):741-56.
    View in: PubMed
    Score: 0.041
  66. A targeted genetic association study of epithelial ovarian cancer susceptibility. Oncotarget. 2016 Feb 16; 7(7):7381-9.
    View in: PubMed
    Score: 0.041
  67. The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiol. 2016 Apr; 41:71-9.
    View in: PubMed
    Score: 0.041
  68. Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiol Biomarkers Prev. 2016 Mar; 25(3):446-54.
    View in: PubMed
    Score: 0.040
  69. Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). J Genet Genome Res. 2015; 2(2).
    View in: PubMed
    Score: 0.040
  70. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecol Oncol. 2016 05; 141(2):386-401.
    View in: PubMed
    Score: 0.039
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.